Sirio Pharma's P/E ratio is typical for moderate growth expectations, but its superior earnings outlook isn't impacting its P/E as expected, indicating potential unseen threats to earnings. Investors anticipate future earnings volatility.

Despite Sirio Pharma's lower returns, reinvestment rise and higher sales are hopeful. But the persistent drop in ROCE and 58% stock slide over three years imply a need for thorough inquiry into more business basics before deciding to invest.